Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||2.95%||10.83||0.7%||$757.06m|
|VRTX||Vertex Pharmaceuticals, Inc.||-1.62%||198.32||1.9%||$408.02m|
|GILD||Gilead Sciences, Inc.||0.09%||68.35||1.0%||$401.65m|
|REGN||Regeneron Pharmaceuticals, Inc.||0.44%||577.13||2.7%||$355.44m|
|NTLA||Intellia Therapeutics, Inc.||-3.72%||136.57||2.3%||$254.07m|
|CRSP||CRISPR Therapeutics AG||1.09%||122.34||0.6%||$146.30m|
|EXAS||EXACT Sciences Corp.||0.52%||108.40||18.1%||$124.23m|
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.